|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Therefore, a meta-analysis was performed to investigate the relation between XIST expression and tumor node metastasis (TNM) stage, lymph node metastasis, distant metastasis, and overall survival of cancer patients.
|
31566056 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of XIST was closely related to the tumor grade, distant metastasis, and FIGO stage in the EOC patients.
|
31564909 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ZEB1 mediated the tumor suppressing roles of XIST knockdown in PC cells.
|
31163263 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, overexpression of XIST was positively correlated with the advanced clinical status of tumors, as well as poor overall survival and DFS.
|
31292221 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The clinicopathological parameters analysis demonstrated that increased XIST expression was significantly associated with tumor size (OR = 2.93, 95% CI = 2.24-3.84; P < .001), clinical stage (OR = 2.73, 95% CI = 1.62-4.58; P < .001) and lymph node metastasis (OR = 2.44, 95% CI = 1.74-3.42; P < .001).
|
30653128 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, increased XIST expression was found to be associated with lymph node metastasis (odds ratio [OR] = 2.06; 95% CI, 1.46-1.90; p < 0.001), distant metastasis (OR = 2.93; 95% CI, 2.00-4.28; p < 0.001), tumor size (OR = 2.66; 95% CI, 1.86-3.81; p < 0.001), poor differentiation (OR = 1.45; 95% CI, 1.00-2.10; p = 0.049), and advanced tumor stage (OR = 3.35; 95% CI, 2.25-5.00; p < 0.001), but not with age (OR = 0.82; 95% CI, 0.59-1.15; p = 0.251) or gender (OR = 0.92; 95% CI, 0.70-1.19; p = 0.512).
|
30341910 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LncRNA X inactive specific transcript (XIST) has been found to function as an oncogene or a tumor suppressor in several cancers.
|
30472203 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Statistical analysis found high XIST expression was correlated with larger tumor size, N1, M1, and topography lymph node metastasis (TNM) III+IV stage of CRC.
|
31452526 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
XIST knockdown repressed NSCLC cell proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) in vitro, and suppressed tumor growth in vivo, while miR-212-3p inhibition restored the effects.
|
31646569 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, XIST positively regulated the expression of P21 through sponging miR-106b-5p, and played a tumor suppressor role in RCC.
|
30717973 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, our findings proved that XIST can serve as a tumor promoter in the pathogenesis of NSCLC, suggesting that XIST has the potential to become a novel therapeutic target for the treatment of NSCLC.
|
31632587 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, functional assays showed that the cell growth ability of HCC cells was inhibited after XIST was silenced in vitro, and tumor formation was inhibited after XIST was silenced in vivo.
|
31799653 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results indicate that XIST plays a critical role in brain metastasis in breast cancer by affecting both tumor cells and the tumor microenvironment and that the XIST-mediated pathway may serve as an effective target for treating brain metastasis.<b>Significance:</b> These findings describe mechanisms of how loss of the lncRNA XIST promotes brain metastasis in breast cancer and identify fludarabine as a potential therapeutic agent that specifically eliminates XIST<sup>low</sup> tumor cells in the brain.<i></i>.
|
30026327 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
For clinicopathological parameters, MALAT1 expression was significantly associated with lymph node metastasis (OR = 2.731; 95% CI: 1.409-5.292; <i>p</i> = 0.003), and high-level expression of XIST was related to larger tumor size (OR = 2.473; 95% CI: 1.159-5.276; <i>p</i> = 0.019) and higher TNM stage (OR = 0.400; 95% CI, 0.184-0.868; <i>p</i> = 0.020).
|
29899709 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
JPX knock-in significantly increased XIST expression and inhibited HepG2 cell growth in vitro or tumor formation in vivo in a XIST dependent manner.
|
30091314 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, silencing of XIST could inhibit tumor growth in vivo.
|
29227532 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The lncRNA X inactive specific transcript (XIST) is a potential tumour suppressor in some types of cancers.
|
29550489 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Xenograft tumor assay was used to verify the role of XIST in DOX resistance in CRC in vivo.
|
30439718 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results showed that expression level of XIST was markedly associated with overall survival (function as oncogene, HR = 0.53, 95% CI: 0.42-0.68, <i>p</i> < 0.00001; function as tumor suppressor, HR = 2.25, 95% CI: 1.15-4.37, <i>p</i> = 0.02), disease free survival (DFS)(HR = 0.45; 95% CI: 0.31-0.67, <i>p</i> < 0.0001), tumor type (digestive system carcinoma, HR = 0.50; 95% CI: 0.37-0.69, <i>p</i> < 0.00001; non-digestive system carcinoma, HR = 0.58; 95% CI: 0.39-0.87, <i>p</i> = 0.008), lymph node metastasis (OR = 0.32, 95% CI: 0.20-0.52, <i>p</i> < 0.00001), distant metastasis (OR = 0.36, 95% CI: 0.22-0.60, <i>p</i> < 0.0001) and tumor stage (OR = 0.43, 95% CI: 0.31-0.60, <i>p</i> < 0.00001).
|
29568404 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Besides, XIST knockdown inhibited tumor growth in vivo.
|
29679755 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This meta-analysis demonstrated that elevated lncRNA XIST expression predicts poor OS, poor DFS, larger tumor size, increased distant metastasis and advanced tumor stage, suggesting that high lncRNA XIST expression may serve as a novel biomarker for poor prognosis and metastasis in cancers.
|
29307668 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
XIST is dysregulated and acts as an oncogene or a tumor suppressor in different human malignancies.
|
30171939 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We were also able to find a global lincRNA deregulation, as the number of lincRNAs transcripts expressed in the tumor was decreased, with a concomitant upregulation of previously described non-coding transcripts associated with cancer, such as MALAT1, MIR181A1HG, CASC1, XIST and FENDRR.
|
29459759 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, we found that XIST was more valuable in digestive system tumors (pooled HR = 2.24, 95% CI: 1.73-2.92) than in non-digestive system tumors (pooled HR = 1.22, 95% CI: 0.60-2.45).
|
29752340 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In thyroid cancer tissues, MET mRNA and protein levels of MET were up-regulated; MET was positively correlated with XIST while negatively correlated with miR-34a, further confirming that XIST serves as a ceRNA for miR-34a through sponging miR-34a, competing with MET for miR-34a binding, and finally modulating thyroid cancer cell proliferation and tumor growth.
|
30463570 |
2018 |